CA3055761A1 - Methods of treatment for kidney disease - Google Patents

Methods of treatment for kidney disease Download PDF

Info

Publication number
CA3055761A1
CA3055761A1 CA3055761A CA3055761A CA3055761A1 CA 3055761 A1 CA3055761 A1 CA 3055761A1 CA 3055761 A CA3055761 A CA 3055761A CA 3055761 A CA3055761 A CA 3055761A CA 3055761 A1 CA3055761 A1 CA 3055761A1
Authority
CA
Canada
Prior art keywords
sdf
kidney
subject
kidney disease
carried out
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3055761A
Other languages
English (en)
French (fr)
Inventor
James K. WILLIAMS
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wake Forest University Health Sciences
Original Assignee
Wake Forest University Health Sciences
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wake Forest University Health Sciences filed Critical Wake Forest University Health Sciences
Publication of CA3055761A1 publication Critical patent/CA3055761A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/195—Chemokines, e.g. RANTES
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1858—Platelet-derived growth factor [PDGF]
    • A61K38/1866—Vascular endothelial growth factor [VEGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Vascular Medicine (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CA3055761A 2017-03-30 2018-03-29 Methods of treatment for kidney disease Pending CA3055761A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762478684P 2017-03-30 2017-03-30
US62/478,684 2017-03-30
PCT/US2018/025063 WO2018183625A1 (en) 2017-03-30 2018-03-29 Methods of treatment for kidney disease

Publications (1)

Publication Number Publication Date
CA3055761A1 true CA3055761A1 (en) 2018-10-04

Family

ID=63678100

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3055761A Pending CA3055761A1 (en) 2017-03-30 2018-03-29 Methods of treatment for kidney disease

Country Status (6)

Country Link
US (2) US11229682B2 (enExample)
EP (1) EP3600251A4 (enExample)
JP (3) JP7667539B2 (enExample)
AU (1) AU2018244776B2 (enExample)
CA (1) CA3055761A1 (enExample)
WO (1) WO2018183625A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2018244776B2 (en) * 2017-03-30 2023-12-14 Wake Forest University Health Sciences Methods of treatment for kidney disease
WO2019032930A1 (en) 2017-08-11 2019-02-14 Wake Forest University Health Sciences USE OF CXCL12 FOR THERAPY AFTER SURGERY OF THE PROSTATE
KR102288446B1 (ko) * 2018-12-28 2021-08-10 서울대학교산학협력단 Cxcl12 검출용 제제를 포함하는 다낭신의 진단용 조성물 및 이의 이용

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2216630T3 (es) 1998-09-09 2004-10-16 Scios Inc Metodos de tratar la hipertension dependiente de la sal.
CA2412436C (en) 2000-06-05 2013-05-21 The Trustees Of Columbia University In The City Of New York Identification and use of human bone marrow-derived endothelial progenitor cells to improve myocardial function after ischemic injury
WO2006124013A2 (en) * 2004-04-30 2006-11-23 Five Prime Therapeutics, Inc. Novel stromal cell-derived factor-1 polypeptides, polynucleotides, modulators thereof, and method of use
CN101287460B (zh) 2005-08-17 2012-04-25 希尔氏宠物营养品公司 预防和治疗肾病的组合物
ES2432395T3 (es) * 2006-10-12 2013-12-03 Ethicon, Inc. Células derivadas de riñon y metodo de uso en la reparación y regeneración tisular
EP2117543A4 (en) * 2007-02-01 2011-09-28 Nephrogen Llc POTENTIALIZATION OF THE IMPLANTATION OF STEM CELLS AND TREATMENT OF ORGAN DYSFUNCTION OR BODY INSUFFICIENCY
ES2520044T3 (es) * 2007-03-30 2014-11-11 The Cleveland Clinic Foundation SDF-1 para su uso en el tratamiento de trastornos vasculares periféricos isquémicos
JP5248519B2 (ja) * 2007-11-07 2013-07-31 小野薬品工業株式会社 Ｓｄｆ−１を含有してなる徐放性組成物
WO2009114826A2 (en) 2008-03-13 2009-09-17 Angiodynamics, Inc. Treatment systems and methods for renal-related diseases
US9694055B2 (en) * 2008-05-09 2017-07-04 Wake Forest University Health Sciences Renal tissue regeneration
JP5856059B2 (ja) 2009-08-28 2016-02-09 ザ クリーブランド クリニック ファウンデーション 虚血組織を治療するためのｓｄｆ−１送達
WO2015089396A1 (en) * 2013-12-13 2015-06-18 Mesoblast International Sarl Methods for repairing tissue damage using protease-resistant mutants of stromal cell derived factor-1
US10420818B2 (en) 2014-05-08 2019-09-24 Wake Forest University Health Sciences Methods of treating incontinence and other sphincter deficiency disorders
KR102314110B1 (ko) 2014-09-16 2021-10-18 삼성디스플레이 주식회사 시각화 가속부를 포함하는 터치 표시 장치
AU2018244776B2 (en) * 2017-03-30 2023-12-14 Wake Forest University Health Sciences Methods of treatment for kidney disease

Also Published As

Publication number Publication date
US20220105156A1 (en) 2022-04-07
US11229682B2 (en) 2022-01-25
JP2020512338A (ja) 2020-04-23
EP3600251A4 (en) 2021-01-13
EP3600251A1 (en) 2020-02-05
AU2018244776A1 (en) 2019-09-19
WO2018183625A1 (en) 2018-10-04
AU2018244776B2 (en) 2023-12-14
JP2023015227A (ja) 2023-01-31
US20200093891A1 (en) 2020-03-26
JP2025069172A (ja) 2025-04-30
JP7667539B2 (ja) 2025-04-23

Similar Documents

Publication Publication Date Title
Ortved Regenerative medicine and rehabilitation for tendinous and ligamentous injuries in sport horses
Hu et al. Islet-1 mesenchymal stem cells-derived exosome-incorporated angiogenin-1 hydrogel for enhanced acute myocardial infarction therapy
Terai et al. Status of and candidates for cell therapy in liver cirrhosis: overcoming the “point of no return” in advanced liver cirrhosis
Serra-Mestre et al. Platelet-rich plasma mixed-fat grafting: a reasonable prosurvival strategy for fat grafts?
Du et al. Mesenchymal stem cells overexpressing C‐X‐C chemokine receptor type 4 improve early liver regeneration of small‐for‐size liver grafts
Liao et al. New progress in angiogenesis therapy of cardiovascular disease by ultrasound targeted microbubble destruction
Chen et al. Injection of autologous bone marrow cells in hyaluronan hydrogel improves cardiac performance after infarction in pigs
Pati et al. Cellular therapies in trauma and critical care medicine: forging new frontiers
JP2025069172A (ja) 腎臓疾患の治療方法
RU2017128296A (ru) Композиция для лечения бесплодия
Sankar New therapeutic strategies to control and treatment of bovine mastitis
Schnabel et al. Use of mesenchymal stem cells for tendon healing in veterinary and human medicine: getting to the “core” of the problem through a one health approach
JP6186572B2 (ja) 薬剤徐放担体及び薬剤徐放方法
Dariolli et al. Allogeneic pASC transplantation in humanized pigs attenuates cardiac remodeling post-myocardial infarction
JP2020512338A5 (enExample)
Xiong et al. The role of platelet concentrates in facial fat grafting
MX360980B (es) Una composición farmacéutica para la estimulación de la angiogénesis.
Gazia et al. Extracellular matrix-based hydrogels obtained from human tissues: A work still in progress
US20160193254A1 (en) Methods and materials for treating arthritis
Connard et al. Current and Emerging Biologic Therapies for Equine Tendon and Ligament Injuries
CN105505857A (zh) 藁本内酯的应用
US9844514B2 (en) Methods for treating an established myocardial infarction
JP2022505468A5 (enExample)
O'Connor et al. A novel cardiac muscle‐derived biomaterial reduces dyskinesia and postinfarct left ventricular remodeling in a mouse model of myocardial infarction
Efimenko et al. Secretome of multipotent mesenchymal stromal cells as a promising treatment and for rehabilitation of patients with the novel coronaviral infection

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220513

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 7TH ANNIV.) - STANDARD

Year of fee payment: 7

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250224

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20250224

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250224

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20250611

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20251006

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20251203

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20251203

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20251203

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 8TH ANNIV.) - STANDARD

Year of fee payment: 8

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20260303

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20260303